Supernus Pharmaceuticals (SUPN) Competitors

$48.21 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

Should you buy Supernus Pharmaceuticals stock or one of its competitors? MarketBeat compares Supernus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	8.49	$99.65M	$0.35	172.06
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.73 beat Supernus Pharmaceuticals' score of 0.63 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics presently has a consensus price target of $70.83, indicating a potential upside of 17.62%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 28.95%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corcept Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Nektar Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Nektar Therapeutics currently has a consensus target price of $149.63, indicating a potential upside of 124.63%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 28.95%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	40.75	-$164.08M	-$8.42	N/A
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A

In the previous week, Nektar Therapeutics and Nektar Therapeutics both had 3 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.63 beat Nektar Therapeutics' score of -0.03 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Supernus Pharmaceuticals beats Nektar Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Perrigo?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Supernus Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Supernus Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Perrigo	-43.50%	9.96%	3.90%

95.9% of Perrigo shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 2 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.63 beat Perrigo's score of 0.22 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Supernus Pharmaceuticals presently has a consensus price target of $62.17, suggesting a potential upside of 28.95%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 72.51%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Supernus Pharmaceuticals beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Pacira BioSciences currently has a consensus target price of $29.40, suggesting a potential upside of 25.91%. Supernus Pharmaceuticals has a consensus target price of $62.17, suggesting a potential upside of 28.95%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pacira BioSciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

In the previous week, Pacira BioSciences had 4 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 7 mentions for Pacira BioSciences and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.63 beat Pacira BioSciences' score of 0.37 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	194.58
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Omeros?

Omeros (NASDAQ:OMER) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Omeros has a beta of 2.66, suggesting that its stock price is 166% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

In the previous week, Omeros had 5 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Omeros and 3 mentions for Supernus Pharmaceuticals. Omeros' average media sentiment score of 0.88 beat Supernus Pharmaceuticals' score of 0.63 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.8% of Omeros shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omeros has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	16.37
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A

Omeros presently has a consensus price target of $40.33, suggesting a potential upside of 251.95%. Supernus Pharmaceuticals has a consensus price target of $62.17, suggesting a potential upside of 28.95%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Omeros beats Supernus Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.80B	$5.88B	$6.46B	$12.34B
Dividend Yield	N/A	0.72%	2.76%	5.28%
P/E Ratio	-94.53	8.59	21.22	25.66
Price / Sales	3.89	20.97	562.28	86.31
Price / Cash	12.77	8.40	43.49	56.67
Price / Book	2.60	4.20	10.31	7.14
Net Income	-$38.55M	$102.24M	$3.57B	$335.98M
7 Day Performance	1.24%	5.42%	6.43%	4.15%
1 Month Performance	-3.11%	0.90%	3.57%	2.54%
1 Year Performance	50.19%	133.78%	34.07%	35.06%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	3.7146 of 5 stars	$48.21 flat	$62.17 +28.9%	+50.2%	$2.80B	$718.95M	N/A	580	Analyst Downgrade
CORT Corcept Therapeutics	3.8452 of 5 stars	$56.36 +2.2%	$70.83 +25.7%	-23.5%	$6.04B	$761.41M	160.88	300	Analyst Revision
NKTR Nektar Therapeutics	2.9898 of 5 stars	$65.34 -4.5%	$149.63 +129.0%	+578.9%	$2.21B	$55.23M	N/A	220	Gap Up
PRGO Perrigo	4.3696 of 5 stars	$10.76 +0.8%	$19.33 +79.6%	-57.7%	$1.49B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	3.3969 of 5 stars	$22.73 +1.3%	$29.40 +29.4%	-9.3%	$891.24M	$726.41M	188.76	720

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Is CORT or SUPN more profitable?

Which has stronger valuation & earnings, CORT or SUPN?

Do institutionals & insiders believe in CORT or SUPN?

Does the media favor CORT or SUPN?

Do analysts rate CORT or SUPN?

Which has more risk and volatility, CORT or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Which has more volatility and risk, NKTR or SUPN?

Do analysts rate NKTR or SUPN?

Is NKTR or SUPN more profitable?

Which has better earnings and valuation, NKTR or SUPN?

Does the media favor NKTR or SUPN?

Do institutionals and insiders believe in NKTR or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Which has more risk and volatility, SUPN or PRGO?

Which has better earnings and valuation, SUPN or PRGO?

Is SUPN or PRGO more profitable?

Do insiders and institutionals hold more shares of SUPN or PRGO?

Does the media prefer SUPN or PRGO?

Do analysts prefer SUPN or PRGO?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Is PCRX or SUPN more profitable?

Do analysts prefer PCRX or SUPN?

Do institutionals & insiders hold more shares of PCRX or SUPN?

Which has more volatility and risk, PCRX or SUPN?

Does the media favor PCRX or SUPN?

Which has higher earnings & valuation, PCRX or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Is OMER or SUPN more profitable?

Which has more volatility & risk, OMER or SUPN?

Does the media favor OMER or SUPN?

Do institutionals and insiders hold more shares of OMER or SUPN?

Which has preferable valuation & earnings, OMER or SUPN?

Do analysts prefer OMER or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools